Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Stock Traders Daily
$20.00
Provider: Pechala's Reports
$15.00
Provider: Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

FDA Panel Supports Broader Use Of Medtronic Inc's Heart Devices-Reuters


Tuesday, 8 Oct 2013 06:34pm EDT 

Reuters reported that a federal advisory panel recommended that Medtronic Inc be allowed to sell certain implantable electronic heart devices to a larger pool of patients, based on study results that showed the products reduced the risk of death and hospitalization. The panel of expert advisers to the U.S. Food and Drug Administration voted 4-3 on October 8, 2013, to recommend that Medtronic be approved to sell the products, called cardiac resynchronization therapy devices, to patients who suffer from an abnormal heart rhythm called atrioventricular block. The devices, also known as CRT-defibrillators and CRT-pacemakers, deliver electrical impulses to both lower chambers of the heart to restore its normal rhythm. 

Company Quote

63.79
0.32 +0.50%
11 Jul 2014